MAM
SNDX icon

Martingale Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Martingale Asset Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-46,315
Closed -$1.18M – 892
2022
Q4 		$1.18M Buy
46,315
+679
+1% +$15.8K 0.02% 411
2022
Q3 		$1.1M Buy
45,636
+35,511
+351% +$797K 0.02% 413
2022
Q2 		$195K Buy
+10,125
New +$169K ﹤0.01% 811

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Martingale Asset Management's SNDX Position: Q1 2023 in Review

Martingale Asset Management sold out of Syndax Pharmaceuticals (SNDX) in Q1 2023, closing a stake of 46,315 shares — an estimated $1.18M sold.

Martingale Asset Management first reported a position in SNDX in Q2 2022 and held it in 3 quarters. The position peaked at $1.18M in Q4 2022. 163 funds tracked by Wall St. Rank hold SNDX as of Q1 2023.

  • Martingale Asset Management reported no remaining Syndax Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Martingale Asset Management sold 46,315 Syndax Pharmaceuticals shares in Q1 2023, an estimated $1.18M.
  • Martingale Asset Management first reported a position in Syndax Pharmaceuticals in Q2 2022 and held it in 3 quarters.
  • Martingale Asset Management's Syndax Pharmaceuticals position peaked at $1.18M in Q4 2022.
  • 163 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2023.

Based on Martingale Asset Management's 13F filing for Q1 2023, filed 12 May 2023.